Microbial DPP-4 inhibitor for Type II diabetes

A daurisoline-based inhibitor of microbial DPP-4 could treat Type II diabetes by decreasing microbial DPP-4-induced degradation of host GLP-1 in the intestinal lumen, which increases active host GLP-1 plasma levels and improves glucose homeostasis.

In human stool-derived bacterial cultures, an activity screen for enzymes produced by intestinal bacteria that possess functions similar to disease-associated human proteins identified 71 microbial-host isozymes, among which statistical analyses identified microbial DPP-4 for its potential to regulate host pathophysiology. In the same cultures, DPP-4 degraded human GLP-1 peptide mimics, with five Bacteroides isolates showing the highest DPP-4 activity. ...